1. Home
  2. EDUC vs CMMB Comparison

EDUC vs CMMB Comparison

Compare EDUC & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Educational Development Corporation

EDUC

Educational Development Corporation

HOLD

Current Price

$1.39

Market Cap

12.1M

ML Signal

HOLD

Logo Chemomab Therapeutics Ltd.

CMMB

Chemomab Therapeutics Ltd.

HOLD

Current Price

$1.71

Market Cap

10.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EDUC
CMMB
Founded
1965
2004
Country
United States
Israel
Employees
N/A
16
Industry
Consumer Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.1M
10.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
EDUC
CMMB
Price
$1.39
$1.71
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$26.50
AVG Volume (30 Days)
24.8K
84.0K
Earning Date
01-08-2026
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.47
N/A
Revenue
$25,371,600.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.02
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.92
$1.60
52 Week High
$1.91
$8.80

Technical Indicators

Market Signals
Indicator
EDUC
CMMB
Relative Strength Index (RSI) 62.72 33.76
Support Level $1.35 $1.70
Resistance Level $1.58 $1.85
Average True Range (ATR) 0.08 0.15
MACD 0.01 0.02
Stochastic Oscillator 57.14 22.50

Price Performance

Historical Comparison
EDUC
CMMB

About EDUC Educational Development Corporation

Educational Development Corp is the United States trade publisher of the line of educational children's books produced in the United Kingdom. Its business activity functions with two reportable segments: PaperPie and Publishing. The Publishing Division segment markets its products to retail accounts, which include books, school supplies, toy and gift stores and museums, through commissioned sales representatives, trade and specialty wholesalers and an internal telesales group.

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.

Share on Social Networks: